| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.06.10 | Kings Dominion Continues Its 'Tribute to the Armed Forces' for the Independence Day Weekend / Free Admission to Past and Present Members of the Military July 4 and 5 | 166 | PR Newswire | DOSWELL, Va., June 26 /PRNewswire/ -- Kings Dominion, is pleased to announce that it will offer FREE admission to active, retired and former United States military personnel on Sunday and Monday... ► Artikel lesen | |
| 26.06.10 | Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin | 44 | PR Newswire | ORLANDO, Florida, June 26, 2010 /PRNewswire/ --
- Not for US Media
Results from a 24-week Phase 3 clinical
study demonstrated that the addition of the investigational... ► Artikel lesen | |
| 26.06.10 | Less Glycemic Variability, Better Patient Reported Outcomes with Lantus and Apidra Regimen vs. Premix Analog Insulin / Study Findings Presented at American Diabetes Association's 70th Annual Scientific Sessions - | 30 | PR Newswire | PARIS, June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA... ► Artikel lesen | |
| 26.06.10 | Orexigen Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression / New Data Presented at American Diabetes Association, 70th Scientific Sessions | 29 | PR Newswire | ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. today announced results from a 24-week open-label study demonstrating that treatment with Contrave® resulted in... ► Artikel lesen | |
| 26.06.10 | Studies Demonstrate Potential Benefits of More-Rapid-Acting Injectable Insulins: Poster Presentations at Annual Meeting of the American Diabetes Association | 15 | PR Newswire | ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ -- Studies of a more-rapid-acting injectable human insulin formulation (VIAject®) in the treatment of type 1 and type 2 diabetes and of a novel... ► Artikel lesen | |
| 26.06.10 | New Data Demonstrates Victoza (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia (sitagliptin) at 52 Weeks | 14 | PR Newswire | ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ -- Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes... ► Artikel lesen | |
| 26.06.10 | Arena Pharmaceuticals' Lorcaserin Reduces Body Weight and Improves Cardiovascular Risk Factors Across Patient Subgroups / Pooled Phase 3 Data Presented at American Diabetes Association's 70th Scientific Sessions - | 33 | PR Newswire | ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical... ► Artikel lesen | |
| 26.06.10 | Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) / Study Presented at ADA 2010 | 12 | PR Newswire | ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical... ► Artikel lesen | |
| 26.06.10 | Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 / Study Showed Improvements Compared to Lantus(R) | 15 | PR Newswire | ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment... ► Artikel lesen | |
| 26.06.10 | Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes / Findings Presented at ADA 2010 | 12 | PR Newswire | ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced results from an analysis of an integrated database of clinical studies that showed no increased... ► Artikel lesen | |
| 26.06.10 | BYDUREON Safety and Tolerability Pooled Summary Data Presented at ADA 2010 / Data from Nearly 1,100 Patients in DURATION-1, -2 and -3 Trials Showed BYDUREON was Well-Tolerated | 11 | PR Newswire | ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced results of an analysis of pooled safety data... ► Artikel lesen | |
| 26.06.10 | Global Security Agency Inc. Announces New Trading Symbol | 11 | PR Newswire | MONTGOMERY, TX, June 25 /PRNewswire-FirstCall/ -- Global Security Agency Inc. (BELV.OB) is pleased to announce that effective at the open of business on June 28, 2010, its common stock will... ► Artikel lesen | |
| 26.06.10 | PSE&G Promotes Paperless Billing Through Sweepstakes / Residents and businesses in PSE&G's service territory can enter for a chance to win $1,000 | 12 | PR Newswire | NEWARK, N.J., June 25 /PRNewswire-FirstCall/ -- Residents and businesses in PSE&G's service territory who sign up for paperless billing or simply mail in a postcard entry in June and July of... ► Artikel lesen | |
| 26.06.10 | DPS Bargained in Good Faith With Williamson Workers, Offered Compensation Package Well Above Local Market Average | 12 | PR Newswire | PLANO, Texas, June 25 /PRNewswire-FirstCall/ -- Dr Pepper Snapple Group today addressed numerous misrepresentations made by the Retail, Wholesale and Department Store Union, which led workers... ► Artikel lesen | |
| 26.06.10 | Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week | 6 | PR Newswire | ORLANDO, Fla., June 25 /PRNewswire-FirstCall/ -- Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TESLA | 2.413 |
| TUI | 1.970 |
| NVIDIA | 1.828 |
| VARTA | 1.685 |
| NEL | 1.534 |
| SUPER MICRO COMPUTER | 1.459 |
| BAYER | 1.291 |
| RHEINMETALL | 1.197 |
| DEUTSCHE BANK | 1.077 |
| RENK GROUP | 988 |
| AIXTRON SE | 979 |
| EVOTEC | 916 |
| SAP | 895 |
| BYD | 788 |
| DEUTSCHE LUFTHANSA | 782 |
| BASF | 738 |
| PLUG POWER | 722 |
| COMMERZBANK | 667 |
| INFINEON | 661 |
| ALLIANZ | 624 |
| NORDEX | 571 |
| MERCEDES-BENZ | 552 |
| THYSSENKRUPP | 516 |
| RWE | 507 |
| DEUTSCHE TELEKOM | 498 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
